论文部分内容阅读
目的:探讨血脂康对急性缺血性脑卒中并高脂血症患者超敏C-反应蛋白变化的影响。方法:将46例患者随机分为辛伐他汀组20例,血脂康组26例,测定调脂治疗前后神经功能缺损评分、血脂和超敏C-反应蛋白等指标。结果:治疗前后两组神经功能缺损评分和总胆固醇均降低、TC/HDL-C比值升高,差异有显著意义(P<0.05),两组间比较差异无显著性(P>0.05);超敏C-反应蛋白水平和甘油三脂均降低。差异有显著意义(P<0.05),两组间比较差异有显著性(P<0.05)。结论:血脂康能治疗急性缺血性脑率中患者,在调脂同时,可减轻炎性损伤。
Objective: To investigate the effects of Xuezhikang on the changes of hypersensitivity C-reactive protein in patients with acute ischemic stroke and hyperlipidemia. Methods: Forty-six patients were randomly divided into simvastatin group (n = 20) and Xuezhikang group (n = 26). Neurological impairment scores, serum lipids and high sensitivity C-reactive protein were measured before and after lipid-lowering treatment. Results: Before and after treatment, the neurological deficit scores and total cholesterol were decreased, and the ratio of TC / HDL-C was increased in both groups (P <0.05). There was no significant difference between the two groups (P> 0.05) Both C-reactive protein levels and triglycerides decreased. The difference was significant (P <0.05), the difference between the two groups was significant (P <0.05). Conclusion: Xuezhikang can treat acute ischemic brain disease in patients with lipid regulation at the same time, can reduce the inflammatory injury.